Forte Biosciences (FBRX) Liabilities and Shareholders Equity (2016 - 2020)
Historic Liabilities and Shareholders Equity for Forte Biosciences (FBRX) over the last 5 years, with Q3 2020 value amounting to $22.7 million.
- Forte Biosciences' Liabilities and Shareholders Equity fell 6787.23% to $22.7 million in Q3 2020 from the same period last year, while for Dec 2020 it was $69.7 million, marking a year-over-year decrease of 7303.35%. This contributed to the annual value of $7.7 million for FY2019, which is 9257.09% down from last year.
- As of Q3 2020, Forte Biosciences' Liabilities and Shareholders Equity stood at $22.7 million, which was down 6787.23% from $28.3 million recorded in Q2 2020.
- In the past 5 years, Forte Biosciences' Liabilities and Shareholders Equity ranged from a high of $110.8 million in Q2 2017 and a low of $7.7 million during Q4 2019
- Its 5-year average for Liabilities and Shareholders Equity is $66.4 million, with a median of $82.0 million in 2018.
- As far as peak fluctuations go, Forte Biosciences' Liabilities and Shareholders Equity soared by 16045.37% in 2017, and later crashed by 9257.09% in 2019.
- Quarter analysis of 5 years shows Forte Biosciences' Liabilities and Shareholders Equity stood at $35.4 million in 2016, then surged by 160.45% to $92.1 million in 2017, then rose by 11.96% to $103.1 million in 2018, then crashed by 92.57% to $7.7 million in 2019, then skyrocketed by 196.81% to $22.7 million in 2020.
- Its Liabilities and Shareholders Equity stands at $22.7 million for Q3 2020, versus $28.3 million for Q2 2020 and $18.6 million for Q1 2020.